| ||
| J&J drug offers hope in advanced prostate cancer Reuters By Ben Hirschler MILAN (Reuters) - Men with advanced prostate cancer lived nearly four months longer on a new pill from Johnson & Johnson, according to keenly awaited study data that researchers said would change clinical practice. ... See all stories on this topic » | ||
| Factbox: Embryonic stem cells: controversial yet powerful Reuters (Reuters) - Doctors have begun testing human embryonic stem cells on a patient for the first time, Geron Corp. said on Monday. Geron has the first US Food and Drug Administration license to use the controversial cells to treat people, ... See all stories on this topic » | ||
| Danish Study Suggests Jaundice-Autism Link BusinessWeek By Jenifer Goodwin MONDAY, Oct. 11 (HealthDay News) -- Newborn babies who have jaundice may be at higher risk of developing autism later on, new research suggests, but other experts said far more research needs to be done before a cause-and-effect ... See all stories on this topic » | ||
| Avastin helps in ovarian cancer but effects fade Reuters By Ben Hirschler MILAN (Reuters) - Roche's blockbuster drug Avastin helps women with ovarian cancer live longer without their disease getting worse, but its effect peaks at 12 months and then diminishes, researchers said on Monday. ... See all stories on this topic » | ||
| FDA Wants More Data For Jazz Pharma Fibromyalgia Drug Wall Street Journal By Kevin Kingsbury and Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--The Food and Drug Administration told Jazz Pharmaceuticals Inc. (JAZZ) it can't approve the company's new-drug application for a fibromyalgia treatment in its present form ... See all stories on this topic » | ||
| Structured Weight Loss Programs Successful CalorieLab Calorie Counter News People who participate in structured weight loss programs are often more successful than those who attempt to diet and exercise on their own, according to new research in the Journal of the American Medical Association. In particular, programs that ... See all stories on this topic » | ||
| Novartis says cancer drug missed goal in study BusinessWeek Swiss drugmaker Novartis AG said Monday that its cancer drug Afinitor did not meet its goal in a late-stage clinical study that tested its ability to treat advanced neuroendocrine tumors. Novartis said patients who were treated with Afinitor did not ... See all stories on this topic » | ||
| FDA Decision to Recall Meridia Came Too Late for Some: Public Citizen AboutLawsuits.com The prominent consumer advocacy group Public Citizen is blasting the FDA over how long it took the federal drug regulator agency to recall Meridia, a prescription weight-loss drug that has been linked to an increased risk of heart attacks and strokes. ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment